This cluster-randomized intervention is embedded in the ComBaCaL (Community-Based Chronic disease care Lesotho) cohort study (EKNZ ID AO\_2022-00058, clinicaltrials.gov ID NCT05596773, Lesotho NH-REC ID 210-2022), a platform for the investigation of chronic diseases and their management in rural Lesotho that is maintained by local lay chronic care village health workers (CC-VHWs). The overall objective of the ComBaCaL cohort study and nested TwiCs is to assess the impact of eHealthsupported, lay-led chronic disease control measures in rural Lesotho. In this T2D TwiC, the effect, safety and feasibility of a community-based T2D care package (which includes the offer of first-line oral antidiabetic and lipid-lowering treatment for uncomplicated T2D by lay CC-VHWs in comparison to facility-based care after community-based screening and diagnosis) will be evaluated.
Globally, 9.3% of the adult population or 436 million individuals were estimated to be living with diabetes in 2019. Until 2045 this number is expected to increase by more than 50% to over 700 million. Four out of five people affected by diabetes are currently living in low- and middle-income countries (LMICs). Over 90% of all diabetes cases are due to type 2 diabetes (T2D) which is also the main driver of the projected increase in overall diabetes cases. The increase in T2D prevalence is caused by ageing populations and changing lifestyles with decreasing levels of physical activity and higher caloric diets and associated obesity. This cluster-randomized intervention is embedded in the ComBaCaL (Community-Based Chronic disease care Lesotho) cohort study (EKNZ ID AO\_2022-00058, clinicaltrials.gov ID NCT05596773, Lesotho NH-REC ID 210-2022), a platform for the investigation of chronic diseases and their management in rural Lesotho that is maintained by local lay chronic care village health workers (CC-VHWs). In this trial, using the Trials within Cohorts (TwiCs) approach, it will be analyzed whether an LHW-led model could be capacitated to safely and effectively provide first-line management (including oral antidiabetic, lipid-lowering treatment and lifestyle counselling) at community-level. In villages randomized to the intervention arm, lay Chronic Care Village Health Workers (CCVHWs) operating within the existing Ministry of Health (MoH) village health worker system will be capacitated to screen for and diagnose T2D, to provide lifestyle counselling, to prescribe and to monitor first-line antidiabetic and lipid-lowering treatment for uncomplicated T2D and to provide treatment support for complicated T2D, supported by a tailored clinical decision support application (ComBaCaL app) in their villages. The control group consists of people diagnosed with T2D living in villages that are also part of the ComBaCaL cohort but not sampled for the intervention (control villages), where CC-VHWs will only screen for and diagnose T2D with subsequent standardized counselling and referral to the closest health facility if T2D is present, but no village-based prescriptions. The overall objective of the ComBaCaL cohort study and nested TwiCs is to assess the impact of eHealthsupported, lay-led chronic disease control measures in rural Lesotho.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Enrollment
252
T2D care package including lifestyle counselling, firstline antidiabetic (metformin) and lipid-lowering (statin) treatment for uncomplicated T2D and treatment support and regular check-ups for complicated T2D at village-level. Guidance will be provided via the ComBaCaL app. In case of complicated disease referral to the closest health facility for further management.
CC-VHWs will refer participants to the responsible health facility for therapeutic management. The ComBaCaL app supports clinical decision making and documentation for screening, diagnosis and referral, but not prescription/provision and monitoring of antidiabetic or lipid-lowering medication for uncomplicated T2D patients or treatment support for complicated T2D patients.
SolidarMed Lesotho
Maseru, Lesotho
University of Basel, Division of Clinical Epidemiology
Basel, Switzerland
Mean HbA1c (in percent)
Mean HbA1c (in percent)
Time frame: 12 months after enrolment
Change in 10-year CVD risk estimated
Change in 10-year CVD risk estimated using the World Health Organization (WHO) CVD risk prediction tool
Time frame: 6 and 12 months after enrolment
Mean HbA1c (in percent)
Mean HbA1c (in percent)
Time frame: 6 months after enrolment
Change in mean fasting blood glucose (FBG) (mmol/l)
Change in mean fasting blood glucose (FBG) (mmol/l)
Time frame: 6 and 12 months after enrolment
Change in proportion of participants with an HbA1c below 8%
Change in proportion of participants with an HbA1c below 8%
Time frame: 6 and 12 months after enrolment
Change in proportion of participants with an FBG below 7 mmol/l
Change in proportion of participants with an FBG below 7 mmol/l
Time frame: 6 and 12 months after enrolment
Change in number of CVD risk factors
Change in number of CVD risk factors (such as smoking status, BMI, abdominal circumference, blood lipid status, blood pressure, dietary habits and physical activity)
Time frame: 6 and 12 months after enrolment
Linkage to care: Change in proportion of participants not taking treatment at enrolment who have initiated pharmacological antidiabetic treatment
Change in proportion of participants not taking treatment at enrolment who have initiated pharmacological antidiabetic treatment
Time frame: 6 and 12 months after enrolment
Engagement in care: Change in proportion of participants who are engaged in care
Change in proportion of participants who are engaged in care, defined as reporting intake of antidiabetic medication as per prescription of a healthcare provider or reaching treatment targets without intake of medication
Time frame: 6 and 12 months after enrolment
Change in self-reported adherence to antidiabetic medication
Change in self-reported adherence to antidiabetic medication
Time frame: 6 and 12 months after enrolment
Occurrence of Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)
Occurrence of Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)
Time frame: within 6 and 12 months after enrolment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.